Geneva, February 25,2026: Switzerland’s approval of the first drug targeting Alzheimer’s marks a noteworthy moment in global health.
The decision means that people in Switzerland now have access to a new medical option for a condition with limited therapeutic choices. Experts say early intervention may help preserve cognitive function for longer in some patients. As Alzheimer’s rates rise globally, developments in diagnosis and treatment are closely watched everywhere, including across the Asia-Pacific region.
